Long Covid

Trial By Error: A Stupid Study of Exercise for Long Covid Patients With Post-Exertional Symptom Exacerbation

By David Tuller, DrPH The Journal of Medical Virology has just published a study called “Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.” The investigators are from the University of Leeds and the Leeds Community Healthcare NHS Trust. Post-COVID-19 syndrome (PCS) …

Trial By Error: A Stupid Study of Exercise for Long Covid Patients With Post-Exertional Symptom Exacerbation Read More »

Trial By Error: Is the Long Covid Phenomenon an Expression of “Psychosocial Distress”?

By David Tuller, DrPH For the second time in a few weeks, a major US news organization has provided Professor Michael Sharpe, lead PACE investigator and one-time Virology Blog commenter, with a high-profile platform to disseminate his typical blather and nonsense. Both articles—the first in New York Magazine, the second in The New Republic–-have presented …

Trial By Error: Is the Long Covid Phenomenon an Expression of “Psychosocial Distress”? Read More »

Trial By Error: The Long COVID Survival Guide and the Role of Patients in Research

By David Tuller, DrPH “The Long COVID Survival Guide: How to Take Care of Yourself and What Comes Next—Stories and Advice from Twenty Long-Haulers and Experts” is pretty much what it sounds like. The anthology was published earlier this month, and each chapter is written by one or more contributors. The topics covered address long …

Trial By Error: The Long COVID Survival Guide and the Role of Patients in Research Read More »

TWiV 953: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses high demand for Amoxicillin causing shortages amid child RSV surge, epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox, low risk of SARS-Cov-2 transmission by fomites, nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection, impact of community masking on COVID-19,  protection against Omicron from vaccination and …

TWiV 953: Clinical update with Dr. Daniel Griffin Read More »

TWiV 951: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective …

TWiV 951: Clinical update with Dr. Daniel Griffin Read More »

TWiV 949: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

Scroll to Top